Clinical Trials Logo

Hyperplasia clinical trials

View clinical trials related to Hyperplasia.

Filter by:

NCT ID: NCT02245529 Completed - Clinical trials for Prostatic Hyperplasia

Safety Profile of Secotex ® in Patients With Benign Prostatic Hyperplasia

Start date: March 2005
Phase: N/A
Study type: Observational

The Objective of this study is to conduct a Prescription Event Monitoring (PEM) involving patients treated with Secotex® (Tamsulosin) in "real life" settings. The aim of a PEM is to monitor the safety profile of Secotex® in a cohort of patients with Benign Prostatic Hyperplasia as used in general practice

NCT ID: NCT02245503 Completed - Clinical trials for Prostatic Hyperplasia

Observational Study of ALNA® (Tamsulosin) in Patients With Benign Prostatic Hyperplasia (BPH)

Start date: May 2003
Phase: N/A
Study type: Observational

The objectives of this post marketing surveillance study were to document the comorbidity and comedication during prescription of ALNA® (Tamsulosin) for patients with BPH (Benign Prostatic Hyperplasia).

NCT ID: NCT02245490 Completed - Clinical trials for Prostatic Hyperplasia

Study to Characterise the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms

Start date: January 2003
Phase: Phase 4
Study type: Interventional

Study to evaluate the efficacy of tamsulosin on storage symptoms and detrusor motor activity in patients with LUTS suggestive of BPH and relevant storage symptoms

NCT ID: NCT02244346 Completed - Clinical trials for Prostatic Hyperplasia

Prescription Event Monitoring in Patients With Benign Prostatic Hyperplasia (BPH)

Start date: May 2004
Phase: N/A
Study type: Observational

Study to evaluate the safety profile of Secotex® in the improvement of the symptoms of Benign Prostatic Hyperplasia in real clinical practice

NCT ID: NCT02244333 Completed - Clinical trials for Prostatic Hyperplasia

Efficacy, Tolerability and Safety of ALNA® in Patients With Benign Prostatic Syndrome (BPS)

Start date: February 2004
Phase: N/A
Study type: Observational

Study to assess efficacy, tolerability and safety parameters of a one month ALNA® - treatment after switch from Terazosin-treatment

NCT ID: NCT02244320 Completed - Clinical trials for Prostatic Hyperplasia

Observational Study in Patients With Functional Benign Prostatic Hyperplasia Symptoms Who Switched From Phytotherapy to ALNA® (Tamsulosin)

Start date: September 2002
Phase: N/A
Study type: Observational

The objective of the observational study were to investigate the switch from phytotherapy to ALNA® after at least 4 weeks of phytotherapy and still presented with a symptom sum score of ≥ 8 points (International Prostate Symptom Score (IPSS))

NCT ID: NCT02244307 Completed - Clinical trials for Prostatic Hyperplasia

Observational Study in Patients Suffering From Benign Prostatic Hyperplasia Treated With Alpha-adrenergic Blockade

Start date: January 2000
Phase: N/A
Study type: Observational

The primary objective of this observational study was the assessment of prognosis factors for having recourse to prostatic surgery in patients with BPH who were administered class-1 alpha blockers. The secondary objectives were the assessment of the time from alpha-adrenergic blockade treatment initiation to surgery and the evolution of patients during the study.

NCT ID: NCT02244294 Completed - Clinical trials for Prostate Hyperplasia

FLOMAX® Versus Placebo, in Male Patients With Acute Urinary Retention Related to Benign Prostatic Hyperplasia (BPH)

Start date: March 2001
Phase: Phase 2
Study type: Interventional

To establish whether the administration of FLOMAX® improves the outcome of a trial without catheter (TWOC) after an episode of acute urinary retention and to determine whether spontaneous voiding is maintained over the course of six months of active treatment

NCT ID: NCT02244268 Completed - Clinical trials for Prostatic Hyperplasia

Study to Evaluate the Effect of ALNA® (Tamsulosin) on the Primary Symptoms of Benign Prostatic Hyperplasia

Start date: October 2000
Phase: N/A
Study type: Observational

The aims of this observational study are to identify the primary BPH symptoms responsible for the patients to consult a urologic practice, resulting in the prescription of ALNA®, to assess the clincial efficacy on an improved occupational performance of the patients being still employed. Additionally to obtain relevant information for the 5-year report of experience with this product according to the requirements in § 49, para 6 of the German Medicines Act.

NCT ID: NCT02244255 Completed - Clinical trials for Prostatic Hyperplasia

FLOMAX® Versus HYTRIN® in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia

Start date: August 1998
Phase: Phase 4
Study type: Interventional

1. To study the early onset of symptomatic relief afforded by FLOMAX® capsules, 0.4 mg daily as compared to HYTRIN® capsules, 5 mg (with titration) daily in patients with the signs and symptoms of benign prostatic hyperplasia (BPH) 2. To evaluate patient's tolerability to the use of FLOMAX® capsules 0.4 mg daily in comparison to HYTRIN® capsules, 5 mg (with titration) daily for the treatment of the symptoms of benign prostatic hyperplasia